HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baser, M. E. Articles by Evans, D. G.R. Search for Related Content PubMed PubMed Citation Articles by Baser, M. E. Articles by Evans, D. G.R. Related Collections All Clinical Neurology All Genetics Neurofibromatosis

Evaluation of clinical diagnostic criteria for neurofibromatosis 2

From Los Angeles, CA (Dr. Baser); Departments of Medical Genetics (Dr. Friedman) and Biostatistics (Dr. Joe), University of British Columbia, Vancouver, Canada; and Department of Medical Genetics (Drs. Wallace and Evans), St. Mary’s Hospital, and Department of Otolaryngology (Dr. Ramsden), Manchester Royal Infirmary, Manchester, UK.

Address correspondence and reprint requests to Dr. Michael E. Baser, 2257 Fox Hills Dr., Los Angeles, CA 90064; e-mail: baser{at}earthlink.net

Background: Four sets of clinical diagnostic criteria for neurofibromatosis 2 (NF2) have been developed by groups of expert clinicians, but sensitivity has never been formally assessed. The sets of criteria differ for people without bilateral vestibular schwannomas, which are pathognomonic for NF2.

Objective: To empirically evaluate the four existing sets of clinical diagnostic criteria for NF2.

Methods: The study was based on 163 of 403 people in the United Kingdom NF2 registry (41%) who presented without bilateral vestibular schwannomas. The authors applied the sets of criteria to each person at initial assessment and at the most recent clinical evaluation (mean ± SE length of follow-up, 13 ± 1 years).

Results: In people with "definite NF2" and a negative family history of NF2, the 1987 US NIH and 1991 NIH criteria each identify 78% of people at the most recent clinical evaluation but 0% at initial assessment. The National Neurofibromatosis Foundation (NNFF) criteria and the Manchester criteria each identify higher proportions at both time points (NNFF criteria, 91% and 10%; Manchester criteria, 93% and 14%), but the proportions at initial assessment are still low.

Conclusions: None of the existing sets of criteria are adequate at initial assessment for diagnosing people who present without bilateral vestibular schwannomas as having NF2, particularly people with a negative family history of NF2. The authors recommend that a single, revised set of diagnostic criteria be devised to replace all of the existing sets of criteria.

This article has been cited by other articles:

				D G. R Evans, R T Ramsden, A Shenton, C Gokhale, N L Bowers, S M Huson, G Pichert, and A Wallace Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification J. Med. Genet., July 1, 2007; 44(7): 424 - 428. [Abstract] [Full Text] [PDF]

				M. Curto, B. K. Cole, D. Lallemand, C.-H. Liu, and A. I. McClatchey Contact-dependent inhibition of EGFR signaling by Nf2/Merlin J. Cell Biol., June 21, 2007; 177(5): 893 - 903. [Abstract] [Full Text] [PDF]

				S. Sathornsumetee, A. DesJardins, D. A. Reardon, J. N. Rich, and J. J. Vredenburgh Neurofibromatosis type 2 Neurology, March 27, 2007; 68(13): E14 - E14. [Full Text] [PDF]

				M. E. Baser, J. M. Friedman, and D. G. R. Evans Increasing the specificity of diagnostic criteria for schwannomatosis Neurology, March 14, 2006; 66(5): 730 - 732. [Abstract] [Full Text] [PDF]

				M. M. Bosch, W. W. Wichmann, E. Boltshauser, and K. Landau Optic nerve sheath meningiomas in patients with neurofibromatosis type 2. Arch Ophthalmol, March 1, 2006; 124(3): 379 - 385. [Abstract] [Full Text] [PDF]

				M E Baser, L Kuramoto, R Woods, H Joe, J M Friedman, A J Wallace, R T Ramsden, S Olschwang, E Bijlsma, M Kalamarides, et al. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2 J. Med. Genet., July 1, 2005; 42(7): 540 - 546. [Abstract] [Full Text] [PDF]

				F. Nunes and M. MacCollin Neurofibromatosis 2 in the Pediatric Population J Child Neurol, October 1, 2003; 18(10): 718 - 724. [Abstract] [PDF]

				C Bovie, S T Holden, A Schroer, E Smith, D Trump, and F L Raymond Neurofibromatosis 2 in a patient with a de novo balanced reciprocal translocation 46,X,t(X;22)(p11.2;q11.2) J. Med. Genet., September 1, 2003; 40(9): 682 - 684. [Full Text] [PDF]

				M. MacCollin, C. Willett, B. Heinrich, L. B. Jacoby, J. S. Acierno Jr., A. Perry, and D. N. Louis Familial schwannomatosis: Exclusion of the NF2 locus as the germline event Neurology, June 24, 2003; 60(12): 1968 - 1974. [Abstract] [Full Text] [PDF]

				A Moyhuddin, M E Baser, C Watson, S Purcell, R T Ramsden, A Heiberg, A J Wallace, and D G R Evans Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring J. Med. Genet., June 1, 2003; 40(6): 459 - 463. [Full Text] [PDF]